$0.92+0.00 (+0.40%)
Arcadia Biosciences, Inc.
Arcadia Biosciences, Inc. in the Consumer Defensive sector is trading at $0.92. The stock is currently near its 52-week low of $0.80, remaining 63.1% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 30/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.10Mβ | $901,000β | $1.30Mβ | $1.46Mβ | $1.20M |
| Gross Profit | $400,000β | $192,000β | $418,000β | $631,000β | $518,000 |
| Operating Income | -$779,000β | -$1.38Mβ | -$1.41Mβ | -$5.99Mβ | -$1.22M |
| Net Income | -$4.38Mβ | -$1.34Mβ | $856,000β | -$4.46Mβ | $2.60M |
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as wel...
DALLAS (AP) β Arcadia Biosciences Inc. RKDA) on Thursday reported a loss of $1.3 million in its fourth quarter. On a per-share basis, the Dallas-based company said it had a loss of 98 cents.
DALLAS (AP) β Arcadia Biosciences Inc. RKDA) on Friday reported earnings of $856,000 in its third quarter. The Dallas-based company said it had net income of 62 cents per share.
DALLAS (AP) β Arcadia Biosciences Inc. RKDA) on Thursday reported a loss of $4.5 million in its second quarter. On a per-share basis, the Dallas-based company said it had a loss of $3.26.